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Introduction 
Aerodigestive fistula (ADF) is the formation of an 
abnormal tract between the airway and the digestive tract, 
most commonly the esophagus. Other terms used in the 
literature include broncho-esophageal, tracheo-esophageal 
or esophagorespiratory fistula. 
ADF occurs in 5–15% of patients with esophageal or lung 
cancer, but may occur after trauma, or as a complication of 
surgery, stent placement and high endotracheal tube cuff 
pressure (1). 
When occurring in the setting of malignancy such as 
lung or esophageal cancers, it is referred to as malignant 
ADF. This leads to significant morbidity and mortality as 
these patients die from pneumonia, sepsis and malnutrition 
within days to weeks if the fistula is left untreated (2-5).
The diagnosis is usually suspected from the clinical 
symptoms and the medical history. Thin section computed 
tomography (CT) scan of the chest and a contrast 
esophagogram provide additional information on the 
location of the fistula. Bronchoscopy and endoscopy are 
necessary to confirm the diagnosis as well as to plan a 
therapeutic intervention. Visualization of small fistula 
can be improved by the administration of oral methylene 
blue prior to the bronchoscopy (6), or by the instillation 
of the methylene blue in the esophagus while performing 
simultaneous bronchoscopic and endoscopic procedures (7). 
Different authors have described the location of the ADF. In 
a series of 63 patients, malignant ADF fistula most commonly 
occurred in the distal third of the trachea in 35%, the middle 
third in 29%, and the left main stem bronchus in 14% of the 
patients (8). In another series of 59 patients, malignant ADF 
occurred in the trachea in 50%, left main bronchus in 32%, and 
right main bronchus in 15% of the patients, while involving 
the main carina in 3% of the cases (9). In another series of 25 
ADF, fistulas were localized to the proximal esophagus in 48%, 
the mid-esophagus in 20% and the distal esophagus in 24% 
of patients. In 8% (2/25) multiple fistulas were present (1). 
Although, most fistulae develop between the central airways 
and esophagus, some fistulae develop between the esophagus 
or stomach and the distal bronchi, small airways or lung 
parenchyma (2,3,10). In patients with esophageal resection for 
esophageal cancer, fistula formation can occur between the 
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stomach that was pulled up into the chest and the airways (11).
The course of thoracic malignant diseases differs 
significantly from those of benign fistula, and thus 
management of ADF should follow a separate approach that 
takes in consideration the patients’ symptoms, quality of life 
and the estimated life expectancy. 
For patients with acquired ADF of benign etiology, 
surgery may provide the best outcome as long as the 
patient is a good surgical candidate. This includes ADF 
division and primary repair, esophageal resection and 
reconstruction, esophageal diversion, suture closure of the 
fistula, pedicled tissue flap, segmental tracheal or bronchial 
resection (12,13).
The majority of patients with malignant ADF have 
either an advanced disease, metastasis or a high Eastern 
Cooperative Oncology Group (ECOG) score making them 
poor surgical candidates. Furthermore, ADF symptoms 
are distressing to patients and can disturb their quality of 
life later in the disease course. As such, palliation of these 
symptoms is recommended (14).
Bronchoscopic and endoscopic therapy is currently the 
main treatment for malignant ADF. In this review, we aim at 
providing an update regarding the latest advances of these 
various therapeutic approaches. 
Endoscopic treatment
Goals of therapy
Patients with TE fistula typically presents with cough and 
dyspnea that is related to aspiration of their saliva and/
or gastric contents. This lead to recurrent pulmonary 
infections and malnutrition with an increased mortality 
when no therapy is provided. Left untreated, patients with 
tracheoesophageal (TE) fistula have a median survival of 
few days to weeks (2-5,15). 
The goals of treatment of the TE fistula is focused on 
palliation of the symptoms including cough, shortness of 
breath, dysphagia, decreasing the risk of aspiration as well 
as on improving the quality of life and survival (16). 
Esophageal stenting only
Esophageal stenting using a self-expanding metallic stent 
(SEMS) has been used since 1980 (7). They are the most 
frequently used treatment modality (1). They are divided into 
partially covered stents and fully covered stents (Figure 1). 
While being equally effective at sealing the ADF, the overall 
clinical success rate at preventing aspiration range from 
54–74% (1,17,18). Partially covered stents tend to embed 
in the esophageal wall making them less prone to migration 
but have a higher rate of tumor ingrowth. Fully covered 
stents have a higher rate of migration (17).
Stent related adverse events have been reported in 
around 30% to 37% of cases (18,19), and can be divided 
into early events (3%), such as esophageal perforation 
and tracheal compression, and late events (27%) such 
as stent migration, stent occlusion by tumor growth, 
upper gastrointestinal bleeding and stent induced fistula 
formation (18). 
The most serious complication that can occur during 
esophageal stent placement is tracheal compression with 
airway compromise. This can occur immediately after 
placement of the esophageal stent or may be a delayed 
complication (18).
Figure 1 Tracheoesophageal fistula. (A) Esophageal view of a 2-mm 
fistula (arrow) with surrounding fibrotic mucosa; (B) endoscopic 
clip (arrow) was attempted but was not optimal due to the fibrotic 
mucosa; (C) the endoscopic clip was removed and covered metallic 
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Airway stenting 
Various types of airway stents have been used for palliation 
of the symptoms of ADF. These can be divided by type 
into partially or fully covered SEMS, silicone stents, and 
dynamic stents, or by shape into straight, L-shaped, I-shaped 
(cylindrical), hourglass-shaped or Y stent (Table 1).
There is a paucity of trials evaluating the role of airway 
stent alone in the management of ADF (Figures 2,3). In 
a retrospective case control study, Chung et al. evaluated 
31 patients who received airway SEMS only for ADF 
and compared them to 28 patients with similar baseline 
demographics who were managed conservatively only (9). 
Median survival, 90-day mortality and performance status 
were higher in the group that received an airway stent. 
Compared to the non-stented group’s median survival of 
29 days, the group who received airway stent had a median 
survival of 69 days.
In another retrospective study done by Wang et al., 
63 patients with malignant ADF who were deemed to be 
non-surgical candidates and who were either unsuitable 
for esophageal stent, had an airway stenosis or had 
a complication from esophageal stenting, received a 
customized metallic airway stent for malignant ADF. A 
total of 45 metallic Y stents, ten I-shaped stents and eight 
L-shaped stents were placed in the airway. Only 8 of these 
patients had additional esophageal stenting. Complete 
fistula closure was observed in 71.4% of the patients (45/63). 
There was an improvement in mean karnofsky score, and an 
overall mean survival of 163 days (8). 
Huang et al. reported their outcome for 50 patients with 
malignant ADF who were managed with esophageal SEMS 
only (21/50), airway SEMS only (13/50) or received double 
stenting (16/50) (20). The mean survival was 171 days, 
with no significant difference between the three groups. 
Complete fistula closure was achieved in 28 of the 50 
patients (56%), with recurrent ADF in 66% of the patients. 
There was no significant difference between the groups. 
In 2010, Herth et al. reported one of the largest 
prospective trials, evaluating 112 patients with malignant 
ADF (21). Thirty-seven patients (33%) received an 
esophageal stent only, 65 patients (58%) received an airway 
SEMS only, and ten patients (9%) received double stenting. 
The mean survival was significantly longer in the group 
receiving an esophageal stent only or double stenting when 
compared to the group receiving an airway stent only 
(269 days vs. 253 and 219 days respectively). The ADF 
primary closure was 100% in all groups, but recurrence 
occurred in 24 patients (21%), and was more common in 
the airway stent only group (17 patients in the airway stent-
only group compared to 6 in the esophageal SEMS-only 
and 1 in the double-stent group).
Double stenting
Double stenting (or parallel stenting) refer to the placement 
of an airway as well as an esophageal stent. Multiple 
studies have reported placement of an esophageal tube (23) 
or SEMS (1,20-22,24). The airway stenting was performed 
using SEMS (1,20-22,24), Silicone stent (1,22-24), 
or dynamic stent (23). In general, these studies are 
retrospective and involve a small number of patients. Few 
allow a direct comparison between single and double 
stenting (20,23,24). 
Freitag et al. (23) published a retrospective study including 
30 patients with malignant ADF who received either a 
Dynamic airway stent alone (12 patients) or combined airway 
and esophageal stenting (18 patients). Patients who received 
double stents had a longer survival compared with the airway 
stent only (110.2 vs. 23.8 days, P=0.0027). Fifty percent of 
the patients who received an airway stent only had persistent 
dysphagia, compared to 11% in the double-stenting group. 
Despite the limitations of the study, the authors concluded 
that double stenting may improve survival and quality of life 
compared to airway stenting alone.
More recently, Ke and his colleagues (24) reported their 
experience in the management of 62 patients with ADF who 
received airway and esophageal stenting. 
Complete response was defined as no leakage of contrast 
medium after digital radiography and resolution of clinical 
symptoms without recurrence for more than two weeks. 
Partial response was defined as minor leakage of contrast 
medium with improvement of clinical symptoms that was 
maintained for more than 2 weeks. Failed treatment was 
defined as severe leakage of contrast medium with no 
improvement in clinical symptoms. Forty-three patients 
received an airway SEMS and 25 of the 43 patients received 
additional esophageal SEMS (double stenting). Complete 
fistula closure occurred in 65 % (28/43) and partial closure 
in 35% (15/43) of the patients. When looking at the double 
stenting group only, 96% (24/25) achieved complete fistula 
closure. Similarly, they inserted 18 airway Dumont silicon 
stents in 18 patients. Ten of these patients received double 
stenting. Complete fistula closure was noted in 72% (13/18) 
and partial closure in 28% (5/18) of the patients. In the 
double stenting group, 100% (10/10) achieved complete 
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Table 1 Summary of studies assessing the role of airway stenting in the management of Aero Digestive Fistula (ADF)
Study Type Patients Outcomes Recurrence Complications
Chung et al. 
2012 (9)
Retrospective case 
control in inoperable 
patient with malignant 
ADF
59 patients: 31 with 
airway SEMS, 28 with 
no SEMS
The group that received an airway 
stent showed: 
 Improved median survival:  
69 vs. 29 days (P=0.04); 
 Improved 90-day mortality: 
42% vs. 14% (P=0.02);
 Less recurrent pneumonia  
(58% vs. 96%);
 Improved performance status
– No major complications 
were reported 
Wang et al. 
2015 (8)
Retrospective study 
in inoperable patients 
with malignant ADF 
with airway stenosis, 
unsuitability for 
esophageal stenting 
or complication from 
esophageal stenting 
63 patients: 
 Metallic airway 
stent in  
55 patients  
(10 I- ,8 L-,  
45 Y-shaped); 
 Double stenting in 
eight patients
The whole group mean survival was 
163 days
– 28 patients with chest 
pain
Complete fistula closure in  
45 (71.4%) patients
Two patients with stent 
migration
Incomplete closure in 18 (28.6%) 
patients
Two patients with double 
stenting had delayed 
massive hemoptysis
Two patients with airway 
restenosis






SEMS, 21 (42%); 
 Double stenting,  
16 (32%); 
 Airway SEMS,  
13 (26%)
Mean survival of all groups was  




up of 178 days
Five patients with chest 
pain after esophageal 
stenting
Primary fistula closure in  
28/50 patients
Some were treated 
with overlapping 
stent in the 
esophagus or the 
airway
One patient with massive 
hemoptysis after tracheal 
stenting
Successful sealing had better 
survival (80 vs. 242 days) P<0.01
Herth et al. 
2010 (21)
Prospective study 




SEMS: 37 (33%); 
 Double stenting:  
10 (9%);
 Airway SEMS:  
65 (58%)
Mean survival of all groups was  
236 days
Recurrence in  
24 patients  
(17 airway,  
1 double and  
6 esophageal) 
after 6 weeks 
requiring a second 
stent placement
Seven patients with 
transient respiratory 
failure requiring MV  
(<1 day) in the ICU  
(4 airways, 2 double and 
1 esophageal stent)
Higher mean survival for the 
esophageal SEMS (269 days) and 
double stenting (253 days) compared 
to airway SEMS only (219 days)
No stent migration
Improved QoL in the whole group No late complication
100% primary closure in all groups
Higher survival for ADF involving 
the trachea/left main and carina 
compared to right mainstem 
bronchus
Higher survival for double or 
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Table 1 (continued)
Study Type Patients Outcomes Recurrence Complications
Silon et al. 
2017 (1)
Retrospective study in 




SEMS, only 13/25 
(52%);
 Double stent 6/25 
(24%); 
 Y [2] + airway 
SEMS [4]
Esophageal SEMS: fistula closure 




procedure in 5/13 
(38%) patients
Minor complications in 
40% (10/25) patients 
including: stent migration, 
pain, dysphagia, bleeding, 
reflux, pneumonia, stent 
infolding and foreign body 
sensation
Double stenting: fistula closure 33% 
(2/6), average survival 3 months
Double stent: 
repeat procedure 
in 2/6 (33%) 
patients
Proximal ADF location—low success 
rate, high recurrence of aspiration, 
shortest survival
Włodarczyk 
et al. 2016 
(22)
Retrospective 
in patients with 
inoperable malignant 
ADF








SEMS + partially 
covered SEMS 
(8/31)
Total mean survival of 68 days  
(3–169 days)
Recurrent fistula 
in 13% (4/31) 
patients
Fatal bleeding in one 
patient on day 3 post 
operation
Improved Karnofsky score Improved 
dyspnea and dysphagia
Seven patients died of 
bleeding in long-term 
follow-up
One patient with 
obliteration of tracheal 
stent by granulation tissue
One patient with 
esophageal stent 
migration





 Esophageal tube 
+ airway dynamic 
Y stent (18/30);
 Airway dynamic Y 
stent (12/30)
Double stenting: mean survival of 
110 days
– Migration of one dynamic 
Y stent
Airway stent only: mean survival of 
24 days
Three dislodgements of 
esophageal tube
Improved dyspnea and dysphagia in 
all groups 





 Airway SEMS:  
43 patients;
 Double stenting in 
25/43; 
 Airway silicone 
stent: 18 patients; 
 Double stenting: 
10/18
Airway SEMS: complete closure, 
28/43 (65%); partial closure, 15/43 
(34.9%); double stenting: complete 
closure, 24/25 (96%) 
– –
Airway silicone stent: complete 
closure, 13/18 (72%); partial closure, 
5/18 (28%); double stenting: 
complete closure, 10/10 (100%)
Metallic stents and silicone stents 
show equivalent clinical effects
ADF, aerodigestive fistula; SEMS, self-expanding metallic stent; QOL, quality of life; MV, mechanical ventilation.
fistula closure. The authors concluded that double stenting 
of the trachea and esophagus can achieve the best clinical 
benefit, and that metallic stents and silicone stents show 
equivalent clinical effects.
These results contrast with those reported by Huang 
et al. (20), who did not find a survival difference between 
patients who received single esophageal, single airway stent 
or double stenting. 
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Overlapping stent
Overlapping refers to the insertion of a second stent in the 
same lumen (esophageal or airway) in which a previous stent 
exists, in order to allow sealing and occlusion of a previously 
stented fistula with incomplete closure. The two stents 
usually overlap over a small distance (Figure 4). Multiple 
studies have described this technique in the management of 
recurrent fistulae (20,21).
Approach to initial stent placement: esophageal versus 
airway stent
In general, an airway stent should be placed first when 
there is a concern for airway compromise, when there is a 
contraindication for esophageal stenting such as esophageal 
obstruction with inability to pass the wire beyond the 
obstruction, if the ADF is located in the upper third of the 
esophagus or if it is technically difficult to place a stent such 
in the case of gastro-tracheal fistula (Figure 2). In patients 
with sufficient nutrition that is provided via percutaneous 
endoscopic gastrostomy, an airway stent only may also be 
inserted (23).
If none of the above conditions are met, it appears that 
esophageal stent only or double stenting have an advantage 
over airway stenting alone. The American College of Chest 
Physicians gives a grade 1B recommendation for double 
stenting of the esophagus and bronchial tree or the esophagus 
alone with SEMS while managing patients with ADF (16).
Technical part 
In general, a multidisciplinary approach by the endoscopist 
Figure 2 Bronchoesophageal fistula. (A) Axial chest CT showing the bronchoesophageal fistula (arrow) between the bronchus intermedius 
and the gastric pull through (post esophageal resection for esophageal cancer); (B) sagital chest CT showing the fistula (arrow); (C) 
bronchoscopic view showing the fistula in the bronchus intermedius (arrow); (D) bronchoscopic view showing the gastric fluid leaking 
through the fistula (arrow) of the bronchus intermedius; (E) endoscopic view showing the gastric fistula (arrow); (F) bronchoscopic view 
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and the bronchoscopist is recommended to provide the 
optimal treatment of the ADF. 
An airway evaluation to determine the degree of airway 
compromise should be done prior to the insertion of any 
esophageal stent. If there is visible airway narrowing, an 
airway stent should be placed first. In cases where there is 
suspicion of impending airway compromise after esophageal 
stent placement, simultaneous dual esophagostomy and 
bronchoscopy during which a balloon can be inflated in the 
esophagus to a diameter equal to that of the esophageal stent 
with direct bronchoscopic evaluation should be done (25). 
If significant airway narrowing develops, the airway 
should be stented first prior to esophageal stenting (26). 
If an airway stent is placed first, it should be followed by 
placement of an appropriately sized esophageal stent, since 
the outcome of double stenting appears better than single 
airway stent. If an esophageal stent is placed first it should 
be followed by an esophagogram in few days to detect 
persistent leak. If such a leak is present an airway stent 
should be placed (Figure 5). 
The optimal stent length should be chosen to cover at 
least 2 cm beyond the proximal and distal margin of the 
lesion. The stent diameter should be at least 10–20% larger 
than the normal internal airway adjacent to the fistula (24).
The choice of the airway stent depends on the location 
of the fistula. Sites with close proximity to the carina may 
benefit from a customized silicone Y stent or dynamic 
airway stent placement, otherwise an appropriately sized 
SEMS or a silicone tube stent can be placed.
Metal stents can be placed with flexible bronchoscopy 
under direct or indirect visualization, using fluoroscopic 
guidance. Metal stent are composed of different metal alloys 
that gives them their radial force and metallic memory, which 
allows them to self-expend after deployment. They can adapt 
Figure 3 Bronchoesophageal fistula. (A) Axial chest CT scan showing the bronchoesophageal fistula between esophagus and left main stem 
(arrow); (B) barium swallow showing the bronchoesophageal fistula (arrow); (C) bronchoscopic view showing the large fistula of the left 
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to different airway size and usually provide a good seal of the 
ADF. They can be fully covered or partially covered. Partially 
covered stents tend to embed in the mucosal wall making 
them less prone to migration, but have a higher rate of tumor 
ingrowth and granulation tissue (17,22). Fully covered stents 
have a higher rate of migration (17).
Silicone stents have similar radial force but require rigid 
bronchoscopy for insertion and tend to have a higher rate 
of migration. They are designed with outer studs to prevent 
migration and cannot conform to the airway anatomy, 
which may decrease their sealing effect.
Complications of airway stenting 
The most serious complications of airway stenting are 
bleeding, enlarging or recurrent fistula, stent migration 
with recurrent aspiration, airway compromise and death. 
These events usually occur as a result of pressure necrosis 
and tissue erosion.
During long-term follow-up, recurrent fistula occurred 
in 13% to 66% of patients (20-22). Massive bleeding can 
occur immediately after stent placement (20,22), or at a 
later stage as reported by Wlodarczyk (7/31 patients) (22), 
and Wang (2/63 patients) (8).
In a review by Herth et al., respiratory failure requiring 
less than one day of mechanical ventilation occurred in 7 out 
of 112 patients (6%) after airway and esophageal stenting (21).
Minor complications such as chest pain, dysphagia, foreign 
body sensation, coughing and stent migration are frequent 
and can occur in up to 40% after stent placement (1).
Figure 4 Complicated aerodigestive fistula. (A) Endobronchial view of a malignant aerodigestive fistula (ADF) of the proximal trachea, 
showing no airway compromise; (B) bronchoscopic view from the proximal trachea showing a displaced airway stent incompletely covering 
the ADF and protruding into the esophagus; (C) bronchoscopic view after repositioning the airway stent and placing an esophageal stent; (D) 
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Other techniques
Several other therapies have been reported in patients 
with TE fistulas. Despite the small number of patients 
evaluated, these techniques carry the potential of closing 
the fistula without the need for major interventions. 
However, one has to remember that technical success with 
all these methods does not always translate into clinical 
success (1). 
Over-the-scope-clips (OTSC)
OTSC were introduced as a mean to close deep wall 
lesions (Figure 6). First reported in 2007 (28), the device 
uses a shape-memory allow (Nitinol). Much larger that 
the older through-the-scope (TTS) clips (29), they are 
deployed using an applicator integrated into the tip of 
an endoscope. The devices are available in several sizes 
(11, 12, and 14 mm), depth (3 and 6 mm) and type of teeth (30). 
Tissue suction is needed for successful application; hence, 
the fistula tissue needs to be soft and extensible (31). As a 
result, the clip is typically applied to the gastrointestinal 
side of the ADF. Overall, they appear to be more effective 
in treating perforations and leaks compared to fistulas (32), 
possibility related to the inability to completely approximate 
the borders that are frequently fibrotic. The technique 
can be used in combination with other modalities (1), such 
as esophageal/airway stenting and endoscopic sutures, 
potentially increasing its chances of clinical success.
Another OTSC system called Padlock Clip (Aponos 
Medical,  Kingston, NH, USA) was more recently 
introduced. It has the advantage of being located alongside 
the shaft of the endoscope, and therefore not requiring the 
working channel for deployment. Armellini et al. described 
its use in a small case series that included two patients with 
ADF (30). Technical success was obtained in all patients. 
Larger studies to determine its role in the management of 
such patients are needed.
Cardiac septal defect occluder
Another potential method of managing TE fistulas is the 
use of atrial septal defect (ASD) and ventricular septal defect 
(VSD) occluders. Made of nitinol, the dumbbell-shaped 
device is made of two discs of different diameters, connected 
by a thin waist. Deployed with the aid of fluoroscopy, each 
disc is positioned on one side of the fistula. Inflammatory 
response with granulation tissue and re-epithelialization 
over the device may occur. The clinical experience 
using these occluders in TE fistulas is limited (33). 
Figure 6 Different types of over-the-scope clips (27). (A) 
Atraumatic version used for gastrointestinal bleeds; (B) traumatic 
version used for closure of leaks; (C) gastric fistula closure version.
Figure 5 Algorithm for management of aerodigestive fistula 






 Contrast esophagogram  confirming ADF
 Bronchoscopy with airway assessment
No airway narrowingCarinal involvementAirway narrowing
Airway stent
Esophageal stent Airway narrowing
Airway stent






Alternative methods, overlapping 







 Y stent Simultaneous EGD with 
esophageal balloon inflation
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Device migration into the airway has been reported (34,35).
 
Septal button
ADF fistula closure has been attempted using silicone septal 
button that are designed to close nasal septal perforation. 
Schmitz et al. described the use of a septal button to 
successfully close a TE fistula after total laryngectomy in 
a case report (36). This resulted in improving the patient’s 
quality of life after failing standard therapies.
Fibrin glue
Closing TE fistula using fibrin glue has been described, 
mainly in the pediatric population. Made of thrombin and 
fibrinogen, fibrin glue has the advantage of immediate 
coagulation when calcium and factor XIII are added 
(through the conversion of fibrinogen to fibrin). If 
successful, it leads to rapid closure and scarring of the 
fistula. It can only be used in small fistulas, and one has to 
be careful about the possibility of major scope damage if the 
glue flows into the working channel (31). In a retrospective 
analysis that included 26 patients with esophageal fistulae 
or leakages, the application of fibrin glue was successful 
in nine cases (37). The remaining patients required other 
endoscopic/surgical interventions or continued to have 
persistent fistula/leakage. In the same study, 9.6% of 
the patients developed an abscess after the endoscopic 
intervention.
Polyglycolic acid (PGA) sheets
Another novel technique is the use of PGA sheets to 
promote the closure of TE fistulas. These are bioabsorbable 
polymers used during surgery to prevent delayed 
perforation by increasing the strength of sutures (29). 
Combined with fibrin glue, reports have described their 
use to enhance the closure of esophago-pulmonary fistula 
and esophago-bronchial fistula (38,39). More studies are 
needed to confirm their efficacy and apparent safety in this 
population.
Mesenchymal stem cells
Transplantation of mesenchymal stem cells is another 
interesting technique that could allow the closure of a 
fistula. Cells harvested from the bone marrow are injected 
into the defect, allowing it to close. In a recent case report, 
Petrella et al. used this technique to close a broncho-pleural 
fistula after a pneumonectomy (40). Even though we could 
not find any report on using this technique in the treatment 
of TE fistula, this could potentially be done for small 
defects.
Others
In a case of distal esophago-pleural fistula secondary to 
Boerhaave’s syndrome, Adler et al. used a combination of 
heat probe and endoscopic suturing to achieve a complete 
closure of the fistula (41). This technique could potentially 
be useful in the management of ADF. Other techniques 
include the use of biodegradable stent. However, the 
experience is limited to the pediatric literature (31). 
Prognosis
Studies looking into prognostic features in patients with 
ADF suggest that achieving complete sealing of the ADF 
after stent therapy is associated with longer survival (80 vs. 
242 days, P<0.01) (20). 
It appears that the location of the ADF may affect 
survival as well. A lower survival was noticed in patients 
with right mainstem involvement when compared to ADF 
involving the trachea, left main bronchus and the carina (21). 
From the esophageal side, proximal esophageal location 
had the shortest survival (4.2 months) compared to distal 
location (7.8 months). Mid esophageal locations have an 
intermediate survival of 6 months (1).
Performance status (ECOG 3 or 4), pulmonary infection 
at the time of SEMS placement, and prior radiation therapy 
were also independent predictive factors associated with 
lower overall survival after stent placement (18). 
Conclusions
Malignant ADF is a devastating condition with high 
morbidity and mortality. Airway and esophageal stenting 
remain the standard of care and is shown to significantly 
improve the quality of life and survival of these patients. 
Although more studies are available to guide our choice of 
therapy, high quality trials to establish the efficacy of each 
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